BGT.AU Bio-Gene Technology Ltd

Healthcare Chemicals Australian Securities Exchange
0.0140 AUD
Close of Oct 30, 2026
0.0125 0.0450
Market cap
AUD 6.13M
P/E
-
P/B
2.93x
ROE
-111.5%
Dividend yield
-
Fundamental score
0.9/5

Ratios use the latest price and the fiscal year ending Jun 2026.

Is BGT.AU undervalued?

Graham number

The Graham number of Bio-Gene Technology Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Bio-Gene Technology Ltd fundamental analysis

5 of 21 checks passed

ROE 0/2

Low return on equity (-111.5%), below 10%.

ROA 0/1

Return on assets (-89.3%) is below the industry median (-35.4%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (38.4%) is above the industry median (-12.5%).

Revenue Growth 0/2

Revenue did not grow over the past 3 years or is not reported.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Cash Runway 1/2

Cash covers 1.0 years of the current cash burn.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 0/1

Price to book (2.9x) is above the industry median (2.2x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Bio-Gene Technology Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Bio-Gene Technology Ltd

Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with James Cook University for experiments demonstrating the value of pre-conditioning bi…

Full company profile